Save Product
Product Details
Source
Chimeric Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) is recombinantly expressed in HEK293. It consists of rabbit variable regions genetically fused to rabbit IgG constant domains.
Antibody Type
Recombinant Monoclonal
Clone
M1C07
Isotype
Rabbit IgG, Kappa
Host Species
Rabbit
Immunogen
NMTi-BSA
Specificity
Specifically recognizes NMTi.
Application
ApplicationRecommended Use / PerformanceELISA0.2-2 μg/mLPurification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364) at 1 μg/mL (100 μL/well) can bind ADC-NMTi with a linear range of 0.5-16 ng/mL (QC tested).
Protocol
Serial dilutions of NMTi, N-Myristoyltransferase inhibitor were added into Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364): ADC-NMTi binding reactions. The half maximal inhibitory concentration (IC50) is 0.37 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364) with ADC-NMTi, Trastuzumab Deruxtecan, Sacituzumab Govitecan, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF conjugated antibody respectively.
The coating antibody was Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including ADC-NMTi, Trastuzumab Deruxtecan, Sacituzumab Govitecan, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364) is specific to ADC-NMTi, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecan, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF (Routinely tested).
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Contact Us
Drug Candidate Licensing
